KR102098032B1 - 지질 이상증 치료제 - Google Patents

지질 이상증 치료제 Download PDF

Info

Publication number
KR102098032B1
KR102098032B1 KR1020157005248A KR20157005248A KR102098032B1 KR 102098032 B1 KR102098032 B1 KR 102098032B1 KR 1020157005248 A KR1020157005248 A KR 1020157005248A KR 20157005248 A KR20157005248 A KR 20157005248A KR 102098032 B1 KR102098032 B1 KR 102098032B1
Authority
KR
South Korea
Prior art keywords
group
cholesterol
compound
hdl
ezetimibe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157005248A
Other languages
English (en)
Korean (ko)
Other versions
KR20150063035A (ko
Inventor
도시아키 다키자와
야수노부 요시나카
Original Assignee
교와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 가부시키가이샤 filed Critical 교와 가부시키가이샤
Publication of KR20150063035A publication Critical patent/KR20150063035A/ko
Application granted granted Critical
Publication of KR102098032B1 publication Critical patent/KR102098032B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157005248A 2012-09-27 2013-09-27 지질 이상증 치료제 Active KR102098032B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27
JPJP-P-2012-214635 2012-09-27
PCT/JP2013/005756 WO2014050134A1 (ja) 2012-09-27 2013-09-27 脂質異常症治療剤

Publications (2)

Publication Number Publication Date
KR20150063035A KR20150063035A (ko) 2015-06-08
KR102098032B1 true KR102098032B1 (ko) 2020-04-07

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157005248A Active KR102098032B1 (ko) 2012-09-27 2013-09-27 지질 이상증 치료제

Country Status (20)

Country Link
US (4) US9572798B2 (https=)
EP (1) EP2902025B1 (https=)
JP (1) JP6238460B2 (https=)
KR (1) KR102098032B1 (https=)
CN (1) CN104640544B (https=)
AU (1) AU2013321918B2 (https=)
BR (1) BR112015006305B1 (https=)
CA (1) CA2901650C (https=)
EA (1) EA024873B1 (https=)
ES (1) ES2752039T3 (https=)
IL (1) IL237981B (https=)
IN (1) IN2015DN02966A (https=)
MX (1) MX357446B (https=)
MY (1) MY177686A (https=)
PH (1) PH12015500471A1 (https=)
PL (1) PL2902025T3 (https=)
PT (1) PT2902025T (https=)
SG (1) SG11201501740XA (https=)
TW (1) TWI598098B (https=)
WO (1) WO2014050134A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
US11419854B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Medicament containing pemafibrate
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物
US11298340B2 (en) * 2017-06-30 2022-04-12 Kowa Company, Ltd. Pharmaceutical composition
US11759456B2 (en) 2017-06-30 2023-09-19 Kowa Company, Ltd. Pharmaceutical composition
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
JP7402687B2 (ja) * 2017-06-30 2023-12-21 興和株式会社 医薬組成物
HRP20241476T1 (hr) * 2017-06-30 2025-01-03 Kowa Company, Ltd. Farmaceutski pripravak
WO2019004453A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬品
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物
TWI891619B (zh) * 2018-12-27 2025-08-01 日商興和股份有限公司 醫藥品
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101636A1 (en) 2003-09-03 2005-05-12 Kowa Co., Ltd. PPAR-activating compound and pharmaceutical composition comprising the compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
JP2008513458A (ja) 2004-09-16 2008-05-01 メルク エンド カムパニー インコーポレーテッド 異常脂質血症及び他の脂質障害の治療用化合物
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101636A1 (en) 2003-09-03 2005-05-12 Kowa Co., Ltd. PPAR-activating compound and pharmaceutical composition comprising the compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Diabetes, 50(6), 1330-1335, 2001.*

Also Published As

Publication number Publication date
AU2013321918B2 (en) 2018-05-10
HK1206620A1 (zh) 2016-01-15
EA024873B1 (ru) 2016-10-31
PL2902025T3 (pl) 2020-03-31
MY177686A (en) 2020-09-23
JP6238460B2 (ja) 2017-11-29
MX357446B (es) 2018-07-10
WO2014050134A1 (ja) 2014-04-03
TW201417811A (zh) 2014-05-16
EP2902025A1 (en) 2015-08-05
BR112015006305B1 (pt) 2020-11-17
CA2901650C (en) 2021-05-04
AU2013321918A1 (en) 2015-04-23
US20170112811A1 (en) 2017-04-27
EP2902025B1 (en) 2019-08-07
IL237981A0 (en) 2015-05-31
US11013722B2 (en) 2021-05-25
CN104640544B (zh) 2017-05-03
PT2902025T (pt) 2019-11-04
US20150196538A1 (en) 2015-07-16
EA201590653A1 (ru) 2015-07-30
CA2901650A1 (en) 2014-04-03
PH12015500471B1 (en) 2015-04-20
EP2902025A4 (en) 2016-03-02
TWI598098B (zh) 2017-09-11
PH12015500471A1 (en) 2015-04-20
MX2015003705A (es) 2015-06-10
SG11201501740XA (en) 2015-04-29
US20180185337A1 (en) 2018-07-05
IN2015DN02966A (https=) 2015-09-18
CN104640544A (zh) 2015-05-20
BR112015006305A2 (pt) 2017-07-04
US20190167645A1 (en) 2019-06-06
IL237981B (en) 2020-05-31
US9572798B2 (en) 2017-02-21
JPWO2014050134A1 (ja) 2016-08-22
US9931321B2 (en) 2018-04-03
KR20150063035A (ko) 2015-06-08
US10258609B2 (en) 2019-04-16
ES2752039T3 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
KR102098032B1 (ko) 지질 이상증 치료제
JP6761346B2 (ja) 脂質異常症治療剤
JP6761347B2 (ja) 脂質異常症治療剤
CN110327331B (zh) 血脂异常症治疗剂
HK1206620B (en) Therapeutic agent for dyslipidemia
HK1237263A1 (en) Dyslipidemia therapeutic agent
HK1237264A1 (en) Dyslipidemia therapeutic agent
HK1219662B (zh) 血脂异常症治疗剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7